Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Stock Information for Candel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Candel Therapeutics Inc.

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
Candel Therapeutics Announces Pricing of Public Offering
Candel Therapeutics Announces Proposed $100 Million Public Offering
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.